IHT Wealth Management LLC bought a new stake in Baxter International Inc (NYSE:BAX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,639 shares of the medical instruments supplier’s stock, valued at approximately $318,000.
Several other institutional investors also recently modified their holdings of the company. 1 North Wealth Services LLC acquired a new stake in shares of Baxter International during the third quarter worth $27,000. Personal Wealth Partners bought a new position in shares of Baxter International in the 2nd quarter worth about $29,000. TRUE Private Wealth Advisors acquired a new position in shares of Baxter International in the 2nd quarter valued at about $29,000. Old North State Trust LLC bought a new stake in shares of Baxter International during the 3rd quarter valued at about $31,000. Finally, Rational Advisors LLC grew its position in shares of Baxter International by 1,808.3% during the 2nd quarter. Rational Advisors LLC now owns 458 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 434 shares during the last quarter. Institutional investors and hedge funds own 82.43% of the company’s stock.
A number of brokerages have issued reports on BAX. ValuEngine cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. JPMorgan Chase & Co. set a $94.00 price target on Baxter International and gave the stock a “buy” rating in a report on Tuesday, October 8th. Finally, Deutsche Bank started coverage on Baxter International in a report on Monday, October 21st. They issued a “buy” rating and a $109.00 price target on the stock. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $89.77.
In other news, SVP Jacqueline Kunzler sold 5,934 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the transaction, the senior vice president now owns 3,089 shares of the company’s stock, valued at $272,202.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Andrew Frye sold 3,332 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $88.00, for a total value of $293,216.00. Following the transaction, the senior vice president now directly owns 16,391 shares in the company, valued at $1,442,408. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 9,446 shares of company stock worth $831,917. 0.70% of the stock is owned by insiders.
Shares of NYSE:BAX opened at $81.86 on Tuesday. The firm’s 50 day moving average is $81.66 and its two-hundred day moving average is $82.72. The firm has a market capitalization of $41.85 billion, a P/E ratio of 25.38, a PEG ratio of 2.11 and a beta of 0.98. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. Baxter International Inc has a 52 week low of $61.40 and a 52 week high of $89.93.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Investors of record on Friday, December 6th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date is Thursday, December 5th. Baxter International’s dividend payout ratio (DPR) is 28.85%.
Baxter International Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: Operating Income
Receive News & Ratings for Baxter International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Baxter International and related companies with MarketBeat.com’s FREE daily email newsletter.